Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types

PURPOSE: The efficacy and safety of regorafenib have been demonstrated in phase 3 trials for multiple tumor types, including metastatic colorectal cancer (mCRC) (CORRECT [NCT01103323]; CONCUR [NCT01584830]), advanced gastrointestinal stromal tumor (GIST) (GRID [NCT01271712]), and hepatocellular carc...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofheinz, Ralf-Dieter, Bruix, Jordi, Demetri, George D, Grothey, Axel, Marian, Marisca, Bartsch, Jennifer, Odom, Dawn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285228/
https://www.ncbi.nlm.nih.gov/pubmed/34285574
http://dx.doi.org/10.2147/CMAR.S305939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285228/
https://www.ncbi.nlm.nih.gov/pubmed/34285574
http://dx.doi.org/10.2147/CMAR.S305939

Ejemplares similares